Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy

BACKGROUND: Prognostic studies of insulin-like growth factor-1 receptor(IGF-1R) inhibitors in cancer therapy had promising results in infratests, which exhibited that IGF-1R signalling was crucial in cancer cells growth. However, the conclusion of later clinical trials revealed a dim future for IGF-...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Xiao, Wu, Zhinan, Dong, Wei, Zhang, Tiehong, Wang, Liguang, Pang, Zhaofei, Ma, Wei, Du, Jiajun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438747/
https://www.ncbi.nlm.nih.gov/pubmed/28427155
http://dx.doi.org/10.18632/oncotarget.15704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438747/
https://www.ncbi.nlm.nih.gov/pubmed/28427155
http://dx.doi.org/10.18632/oncotarget.15704

Ejemplares similares